港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

醫美概念股

869.902

-13.531-1.53%

漲家數：1

跌家數：12

平家數：- -

市盈率：- -

高：884.356

開：882.809

低：858.346

收：883.433

成交量：6,996.06萬

成交額：7.10億

市值：1,445.98億

流通市值：1,067.35億

資料載入中...

康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批

康哲藥業(00867.HK)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批

康哲藥業：德維康產品Lumirix獲國家藥監局批准，用於特應性皮炎治療（2026年9月2日）

麗豐控股(01125)：公眾持股量為14.76%

復星醫藥(02196.HK)：蘆沃美替尼片新增適應症獲註冊批准

復星醫藥(600196.SH)子公司蘆沃美替尼片新增適應症獲註冊批准

大行評級丨招銀國際：時代天使上半年業績勝預期，目標價升至114.21港元

德宏瑞麗：檸香滿邊城金果富農家

三生製藥(01530)9月2日斥資2358.5萬港元回購150萬股

貝萊德在復星醫藥的H股好倉比例上升0.22%至7.19%

南方财经网

大行評級丨大摩：上調時代天使目標價至105港元，上調2026至28年收入預測

時代天使（06699）：雙輪驅動、規模效應、份額躍升，三重成長邏輯重塑全球正畸版圖

蘇南瑞麗航空2026年暑運承運旅客超117萬人次

康哲藥業(00867)、貝殼(02423)、敏實集團(00425)等港股亮相隱形重倉傅鵬博、趙楓調倉路徑揭曉

四環醫藥(00460.HK)授出合共1.16億份股份獎勵

昊海生物科技(06826)9月1日耗資約59.98萬港元回購3.64萬股

時代天使發布2026中期業績：案例數增長40.2%達316609例

每日经济新闻

《業績》時代天使(06699.HK)中期純利2,725萬美元增86% 連特別息派4.57港元

阿斯达克财经

時代天使(06699)2026上半年全球業務加速放量，中國市場份額穩步攀升

瑞麗醫美(02135)註銷4727.64萬份尚未行使購股權

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK1593/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"醫美概念股","latestPrice":869.9022,"timestamp":1789114133774,"preClose":883.43335,"halted":0,"volume":69960617,"delay":0,"changeRate":-0.015317,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-13.531128,"latestTime":"09-11 16:00:00","open":882.80945,"high":884.35583,"low":858.3457,"amount":709509713,"amplitude":0.029442,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":1.117247,"peRate":10.209827,"turnoverRate":0.003127,"increases":1,"decrements":12,"flats":0,"marketCap":144597722624,"floatMarketCap":106735221760},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":884.35583,"amplitude":0.029442,"preClose":883.43335,"low":858.3457,"pbRate":"1.117247","latestPrice":869.9022,"volume":69960617,"delay":0,"open":882.80945,"prevYearClose":1094.978,"prevWeekClose":913.749,"prevMonthClose":902.195,"prevQuarterClose":846.145,"fiveDayClose":913.749,"twentyDayClose":957.712,"sixtyDayClose":841.957,"secType":"PLATE","market":"HK","turnoverRate":0.003127,"peRate":10.209827,"marketCap":144597722624,"floatMarketCap":106735221760,"timestamp":1789114133774,"nameCN":"醫美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":1,"down":12,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664875311","title":"康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875311","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875311?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:01","pubTimestamp":1788429695,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，旗下德镁医药有限公司已于2026年9月2日获得中国国家药品监督管理局批准磷酸芦可替尼乳膏百卢妥轻中度特应性皮炎的新药上市许可申请，并于2026年九月3日获得药品注册证书。2026年1月，百卢妥中国NDA获批，成为中国批准的首款用于白癜风治疗的外用 JAK抑制剂。继百卢妥获批白癜风适应症后，此次AD适应症NDA获批，将进一步拓展产品的临床应用空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK4132","BK1574","IE00BYV24P56.USD","SG9999004220.SGD","IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","BK1191","SG9999015978.USD","SG9999015986.USD","IPOS","BK1161","LNGR","MEDX","SG9999015945.SGD","IE00BGHQDM52.EUR","LU2488822045.USD","IE00BMCWC346.EUR","06978","SG9999015952.SGD","IBBQ","159992","AD","00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664753128","title":"康哲藥業(00867.HK)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664753128","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664753128?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:01","pubTimestamp":1788429695,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00867","BK1593","BK1161","SG9999015952.SGD","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","SG9999015945.SGD","BK1574","IE00BMCWC346.EUR","IE00BYV24P56.USD","SG9999015986.USD","SG9999004220.SGD","IE00BVYPNP33.GBP","LU2488822045.USD","SG9999015978.USD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177316058","title":"康哲藥業：德維康產品Lumirix獲國家藥監局批准，用於特應性皮炎治療（2026年9月2日）","url":"https://stock-news.laohu8.com/highlight/detail?id=1177316058","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177316058?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:56","pubTimestamp":1788429369,"startTime":"0","endTime":"0","summary":"2026年9月2日，康哲药业旗下德维康所提交的Lumirix新药申请，已正式获得国家药品监督管理局的批准，该药物适应症为特应性皮炎。这一获批标志着该产品在相关治疗领域迈出关键一步，为临床提供了新的选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015945.SGD","LU2488822045.USD","IE00BVYPNP33.GBP","IE00BYV24P56.USD","SG9999015986.USD","BK1191","00867","SG9999015952.SGD","IE00BVYPNQ40.USD","SG9999015978.USD","BK1593","SG9999004220.SGD","IE00BMCWC346.EUR","IE00BGHQDM52.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664634873","title":"麗豐控股(01125)：公眾持股量為14.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664634873","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664634873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:41","pubTimestamp":1788428501,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽丰控股(01125)发布公告，于本公布日期，公司之公众持股量为14.76%，仍低于上市规则规定公司全部已发行股本之25%须由公众人士持有之水平。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01125","BK1240","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664781028","title":"復星醫藥(02196.HK)：蘆沃美替尼片新增適應症獲註冊批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664781028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664781028?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:22","pubTimestamp":1788427355,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02196","BK1515","BK1191","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664264827","title":"復星醫藥(600196.SH)子公司蘆沃美替尼片新增適應症獲註冊批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664264827","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664264827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:21","pubTimestamp":1788423715,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复星医药产业发展有限公司就芦沃美替尼片(商品名：复迈宁、项目代号：FCN-159)新增适应症的药品注册申请获国家药品监督管理局批准，本次获批的新适应症为用于伴有症状、无法手术的丛状神经纤维瘤(PN)的I型神经纤维瘤病(NF1)成人患者。该药品为集团自主研发的创新型小分子化学药物，为MEK1/2选择性抑制剂。本次新增适应症获批，可为中国境内相关罕见肿瘤患者提供新的治疗选择，并进一步增强该药品的市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","600196","BK0183","BK1515","BK0060","BK1191","BK1593","BK0196","BK0188","BK0028","BK0187","BK0096","02196","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664213498","title":"大行評級丨招銀國際：時代天使上半年業績勝預期，目標價升至114.21港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664213498","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664213498?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:12","pubTimestamp":1788415941,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06699","BK1583","BK1587","BK1593","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664281209","title":"德宏瑞麗：檸香滿邊城 金果富農家","url":"https://stock-news.laohu8.com/highlight/detail?id=2664281209","media":"云南网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664281209?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 21:37","pubTimestamp":1788356220,"startTime":"0","endTime":"0","summary":"金秋时节，走进云南省德宏州瑞丽市的田间地头，漫山遍野的柠檬树郁郁葱葱，金黄饱满的果实挂满枝头，空气中弥漫着淡淡的清香。据勐秀乡副乡长许叁卫介绍，目前全乡柠檬种植面积已达28000亩，每年产量3万余吨，市值达1.5亿元。2023年，云南瑞垦巍小檬科技有限公司落户瑞丽，重点发展香水柠檬种植。截至目前，瑞丽市柠檬种植总面积已达32000亩，投产面积达24300亩。2026年，全市预计总产量达26730吨，总产值突破2亿元，直接带动农民人均增收1678元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-02/doc-iniqnawn4522270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1209","BK1593","02135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664181643","title":"三生製藥(01530)9月2日斥資2358.5萬港元回購150萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664181643","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664181643?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:29","pubTimestamp":1788348580,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年9月2日斥资2358.5万港元回购150万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000165453.HKD","01530","BK1583","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664818325","title":"貝萊德在復星醫藥的H股好倉比例上升0.22%至7.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664818325","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664818325?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 17:24","pubTimestamp":1788341040,"startTime":"0","endTime":"0","summary":"南财智讯9月2日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在复星医药的H股好仓（L）比例于8月28日从6.97%上升至7.19%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862836877.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862836877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0188","BK0187","BK0175","BK0239","600196","BK0183","BK0196","BK1515","BK0060","BK1593","BK1191","BK0028","02196","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664182896","title":"大行評級丨大摩：上調時代天使目標價至105港元，上調2026至28年收入預測","url":"https://stock-news.laohu8.com/highlight/detail?id=2664182896","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664182896?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 13:44","pubTimestamp":1788327871,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1593","06699","BK1587","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664898930","title":"時代天使（06699）：雙輪驅動、規模效應、份額躍升，三重成長邏輯重塑全球正畸版圖","url":"https://stock-news.laohu8.com/highlight/detail?id=2664898930","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664898930?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 10:22","pubTimestamp":1788315774,"startTime":"0","endTime":"0","summary":"8月31日，时代天使交出了一份超市场预期的中期成绩单，业务成果和财务指标的强劲表现，标志着公司基本面已迎来实质性的突破。智通财经APP认为，时代天使此次中报最大的看点在于盈利质量的跃升与增长逻辑的兑现。2026年上半年，时代天使中国内地市场隐形矫治案例数达到148608例，同比增长36.8%。综上，时代天使2026年中期业绩所释放的核心信号，是公司已形成更均衡、更具韧性的全球增长结构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06699","BK1100","BK1587","BK1583","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664507498","title":"蘇南瑞麗航空2026年暑運承運旅客超117萬人次","url":"https://stock-news.laohu8.com/highlight/detail?id=2664507498","media":"云南网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664507498?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 23:28","pubTimestamp":1788276480,"startTime":"0","endTime":"0","summary":"2026年暑运圆满落下帷幕。面对客流高位运行、雷雨台风叠加的多重考验，苏南瑞丽航空累计承运旅客超117万人次，创历年暑运新高，用专业与坚守守护每段安稳航程。今年暑运台风频发、雷雨集中，运行环境复杂多变。暑运累计保障无陪、轮椅、首乘、盲人等特殊旅客1000余人次，收到表扬信30封、锦旗2面。从地面到空中，从产品到体验，苏南瑞丽航空以专业守护旅途、以温度点亮云端，为117万旅客交出了一份安心暖心的暑运答卷。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-01/doc-iniqixxs8249051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02135","159231","BK1593","BK1209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664854692","title":"康哲藥業(00867)、貝殼(02423)、敏實集團(00425)等港股亮相隱形重倉 傅鵬博、趙楓調倉路徑揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2664854692","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664854692?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 21:19","pubTimestamp":1788268792,"startTime":"0","endTime":"0","summary":"具体来看，截至2026年6月末，傅鹏博和朱璘管理的睿远成长价值混合“隐形重仓股”依次为：联讯仪器、寒武纪、中钨高新、沪电股份、福瑞股份、蓝晓科技、敏实集团、生益科技、康哲药业、天孚通信。睿远基金另一位明星基金经理赵枫管理的睿远均衡价值三年持有则首次建仓陕西煤业，同时大幅增持了贝壳、杭州银行，这与其在报告中强调的“寻找除AI外具备静态回报水平吸引力的资产”思路相吻合。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0244354667.USD","LU1051769294.HKD","LU1831875114.USD","BK1191","BK1144","BK4548","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","IE00BYV24P56.USD","LU0651946864.USD","BK1509","00867","LU2488822045.USD","LU0463099449.HKD","IE00BVYPNP33.GBP","LU0359201612.USD","BK4505","LU0359201885.HKD","BK4526","LU0359202008.SGD","LU1051768304.USD","SG9999004220.SGD","LU0651947912.USD","BK4585","BK1097","LU0173614495.USD","LU1188198961.HKD","LU2476274308.USD","IE00BVYPNQ40.USD","BK4504","LU0326950275.SGD","VXUS","SG9999015952.SGD","SG9999015978.USD","00425","BK1589","LU0287142896.SGD","BK1593","LU1688375341.USD","SG9999015986.USD","SG9999015945.SGD","LU1023057109.AUD","BK4588","BEKE","LU1515016050.SGD","02423","BK4079","KCAI","LU2778985437.USD","BK4509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385197","title":"四環醫藥(00460.HK)授出合共1.16億份股份獎勵","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385197","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664385197?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 21:01","pubTimestamp":1788267673,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1600","BK1191","BK1593","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664373158","title":"昊海生物科技(06826)9月1日耗資約59.98萬港元回購3.64萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664373158","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664373158?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 17:18","pubTimestamp":1788254331,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)公布，2026年9月1日耗资约59.98万港元回购3.64万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06826","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664824578","title":"時代天使發布2026中期業績：案例數增長40.2%達316609例","url":"https://stock-news.laohu8.com/highlight/detail?id=2664824578","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664824578?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 10:05","pubTimestamp":1788228324,"startTime":"0","endTime":"0","summary":"8月31日，时代天使（HK6699）发布2026中期业绩，截至2026年6月30日止六个月，公司总案例数达到316609例，同比增长40.2%；公司收入及净利润同比增长分别达到42.9%和79.6%。报告期内，公司全球市场（中国内地除外）隐形矫治案例总数达到168,001例，同比增长43.4%，并实现盈利；中国内地市场案例数达到148,608例，同比增长36.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013861226010.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013861226010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06699","BK1593","BK1587","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663776004","title":"《業績》時代天使(06699.HK)中期純利2,725萬美元增86%  連特別息派4.57港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663776004","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663776004?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 23:31","pubTimestamp":1788190260,"startTime":"0","endTime":"0","summary":"时代天使(06699.HK) 公布6月止六个月中期业绩，收入2.31亿美元，按年增加43%；毛利1.45亿美元，上升43.8%。录得纯利2,725万美元，增长86.1%，每股盈利16美仙。中期息47港仙，另派特别息4.1港元。(d)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-31 16:25。)过往派息公布日期派息事项派息内容2026/03/27末期业绩特别股息：港元 4.99002026/03/27末期业绩股息：港元 0.48002025/08/25中期业绩特别股息：港元 0.46002025/03/20末期业绩特别股息：港元 0.3800AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210618164758811_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210618164758811_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542269/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542269/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","BK1587","BK1593","06699","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663005319","title":"時代天使(06699)2026上半年全球業務加速放量，中國市場份額穩步攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2663005319","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663005319?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 20:56","pubTimestamp":1788180973,"startTime":"0","endTime":"0","summary":"2026年上半年，临床医生对真正以临床需求为导向的产品和服务越来越重视，推动时代天使业务实现快速增长。截至目前，公司累计服务病例已超过200万例，市值达到20亿美元。时代天使于2021年在香港联合交易所上市，自2023年启动全球化战略以来，产品和服务已覆盖全球60多个国家和地区。除法律要求外，时代天使不承担因新信息、未来事件或其他原因导致更新任何前瞻性声明的义务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1583","BK1100","BK1587","06699"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663983070","title":"瑞麗醫美(02135)註銷4727.64萬份尚未行使購股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2663983070","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663983070?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 19:35","pubTimestamp":1788176103,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞丽医美(02135)发布公告，经董事会批准(包括经薪酬委员会批准)，根据购股权计划向若干合资格人士(承授人)授出的以下全部4727.64万份尚未行使购股权已自2026年8月31日起注销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1209","BK1593","02135"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":72,"code":"91000000","status":"200"}]}}